The interim recommendation made by the National Drug Scheduling Advisory Committee (NDSAC) on June 7, 2026, that:

• Bisacodyl, when sold in strengths of 10 mg or less per rectal dosage unit/suppository, in package sizes containing no more than 70 mg of bisacodyl, be granted Unscheduled status.

was finalized effective July 21, 2026. Final approval of the interim recommendation was made by NAPRA’s Board of Directors, in consideration of comments received during the 30-day consultation period. The National Drug Schedules will be revised accordingly.